. 2013 May 5;3(2):141–164.

Table 1.

Cytogenetic/molecular risk categories and clinical outcomes

Cytogenetic risk category	Karyotype	Complete remission	Overall survival	References
Favorable	t(15;17), t(8;21), inv(16)	75-88%	3-yr 38%	[8,19,32,117,118]
	-OR-		5-yr 17-38%
	Normal karyotype with NPM1 ^mut/FLT3 ^wt	68-83%	3-yr 29-33%	[26,28,32]
			5-yr OS 21%
Intermediate	Normal karyotype not associated with favorable molecular markers; cytogenetic abnormalities not included in other groups	51-63%	3-yr 18%	[8,19]
Intermediate		51-63%	5-yr 11-16%	[8,19]
Adverse	Complex (3 or more, not including a favorable abnormality), monosomy (especially complete or partial deletion of 5 or 7), inv(3), t(9;22), 11q23 or 17p abnormalities	26-40%	3-yr < 5%	[15,18,19,32,117]